Loading organizations...
Samphire Neuro develops non-invasive neurotechnology devices aimed at addressing women's health concerns. The company's core product is a head-mounted therapeutic wearable that utilizes low electrical current brain stimulation, specifically tDCS, to provide support for symptoms such as period pain, low mood, and brain fog, without relying on hormones or drugs. This approach leverages neuroscience to target brain circuits associated with menstrual-related discomforts.
Dr. Emilė Radytė, a neuroscientist with academic credentials from Harvard and Oxford, co-founded Samphire Neuro. Her insight stemmed from the need for innovative, drug-free solutions to significantly improve women's health, particularly for widespread conditions like menstrual pain, PMS, and PMDD. Her background in neuroscience underpins the company's scientific foundation and its brain-based innovation strategy.
The product serves women experiencing a range of menstrual health issues, including pain, PMS, PMDD, and endometriosis-related symptoms. Samphire Neuro's vision centers on transforming women's health by offering effective, non-pharmacological interventions. The company aims to redefine care paradigms through neurotechnology, providing accessible and science-backed support for chronic and cyclical conditions.
Samphire Neuroscience is a UK-based medtech startup building non‑pharmaceutical neurotechnology for women’s chronic reproductive health; its flagship product, Nettle, is a CE‑marked wearable transcranial stimulation headband designed to reduce menstrual pain and mood symptoms and the company is scaling commercially and clinically into new markets.[2][1]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Samphire Neuroscience is a clinically oriented femtech neurotechnology startup that has moved beyond concept stage—CE‑marked product, trials and early international sales—and now faces the critical next phase of US regulatory progress and broader clinical adoption that will determine whether it establishes a durable category in women’s brain and pain care.[1][2][3]